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Background: blaVEB-1 is an integron-located extended-spectrum β-lactamase gene
initially detected in Escherichia coli and Pseudomonas aeruginosa strains from south-
east Asia. Several recent studies have reported that VEB-1-positive strains are highly
resistant to ceftazidime, cefotaxime and aztreonam antibiotics. One strategy to
overcome resistance involves administering antibiotics together with β-lactamase
inhibitors during the treatment of infectious diseases. During this study, four VEB-1
β-lactamase inhibitors were identified using computer-aided drug design.
Methods: The SWISS-MODEL tool was utilized to generate three dimensional
structures of VEB-1 β-lactamase, and the 3D model VEB-1 was verified using
PROCHECK, ERRAT and VERIFY 3D programs. Virtual screening was performed by
docking inhibitors obtained from the ZINC Database to the active site of the VEB-1
protein using AutoDock Vina software.
Results and conclusion: Homology modeling studies were performed to obtain a
three-dimensional structure of VEB-1 β-lactamase. The generated model was
validated, and virtual screening of a large chemical ligand library with docking
simulations was performed using AutoDock software with the ZINC database. On the
basis of the dock-score, four molecules were subjected to ADME/TOX analysis, with
ZINC4085364 emerging as the most potent inhibitor of the VEB-1 β-lactamase.
Keywords: VEB-1 β-lactamase, Homology modeling, Virtual screening, Docking,
InhibitorBackground
blaVEB-1 was identified in 1996 from an Escherichia coli strain isolated from a Vietnamese
patient. Subsequent analysis demonstrated that blaVEB-1 is both plasmid- and integron-
located [1,2]. Among the different Ambler class A expanded-spectrum β-lactamase
(ESBL) genes, blaVEB-1 is considered to be “emerging”; it has been detected in several
Gram-negative organisms including Enterobacteriaceae and Pseudomonas aeruginosa
[3,4], and in multiple countries including France, Spain, Algeria, Turkey, Canada, Korea,
Thailand and Tunisia [5-10]. Furthermore, P. aeruginosa isolates producing the VEB-1a
variant, which differs from VEB-1 by only a single amino acid located in the leader pep-
tide of the pre-mature protein, have been identified in Kuwait and India [11,12]. VEB-1
has high amino-acid identity to PER-1 and PER-2 (38%) EBSLs, and confers high-level© 2013 Messaoudi et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
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http://www.tbiomed.com/content/10/1/22resistance to ceftazidime, cefotaxime and aztreonam [13]. The blaVEB-1 gene was charac-
terized in an unusual genetic environment in P. aeruginosa isolates from India and
Bangladesh, and in P. stuartii from Algeria. Rather than having a typical class 1 integron
structure, in these isolates blaVEB-1 is flanked by identical 135-bp sequences, termed re-
peated elements (Res), which are bracketed by two truncated 30-conserved class 1 integron
sequences in direct repeat [14].
There are currently no clinically useful inhibitors of VEB-1 β-lactamase. How-
ever, several studies have been undertaken using a variety of experimental inhibi-
tors against other Ambler class A ESBLs. Clavulanic acid, the first β-lactamase
inhibitor introduced into clinical medicine, was isolated from Streptomyces
clavuligerus during the 1970s [15]. Clavulanate (the salt form of the acid in solu-
tion) presented with little antimicrobial activity in isolation, but when combined
with amoxicillin, it significantly lowered amoxicillin MICs against Staphylococcus
aureus, Klebsiella pneumoniae, Proteus mirabilis and E. coli [16]. Sulbactam and
tazobactam are penicillinate sulfones developed as synthetic compounds in 1978
and 1980, respectively [17,18]. Class A β-lactamase is inhibited to comparable
levels by moxalactam, imipenem and cefoxitin.
The crystal structure of VEB-1 β-lactamase has not been described. Determining
the three-dimensional (3D) structure of this molecule would assist in the discovery
of more potent inhibitors, particularly in the application of structure-based virtual
screening to identify lead compounds. To this end, a homology model of the 3D
structure of VEB-1 protein was produced and a computational docking process was used
to identify a series of potent inhibitors from the ZINC Database to allow VEB-1 to be com-
pared with other Class A β-lactamase complexes.Methods
Template identification and protein homology modeling
Searching the RCSB Protein Data Bank (http://www.rcsb.org/) confirmed that the
tertiary structure of VEB-1 β-lactamase was not publicly available. The complete E.
coli VEB-1 β-lactamase protein sequence, which consists of 299 amino acids and has
a calculated molecular weight of 33.7 kDa, was retrieved from the UniProtKB data-
base (http://www.uniprot.org/) (accession number Q7BVU7). BLASTP [19] was used
to identify homologs in the RCSB Protein Databank [20]. Accordingly, the crystal
structure of PER-1 β-lactamase from P. aeruginosa (PDB ID: 1E25), which has 40%
sequence identity to VEB-1, was selected as the template [21]. To analyze sequence
conservation, the VEB-1, PER-1, CTX-M and Toho-1 sequences were aligned. Gaps
were inserted into the sequences to discover an optimal alignment, as presented in
Figure 1A. The 3D structure of VEB-1 was modeled using the SWISS-MODEL tool
[22] in the ExPASy Bioinformatics resource portal [23], and viewed using Swiss PDB
Viewer v 4.0.1 software [24].Model optimization and evaluation
Protein models generated using homology modeling frequently produce unfavorable
bond lengths, bond angles, torsion angles and contacts. Therefore, it was essential to
Figure 1 Overall structure of VEB-1 and its sequence alignment with its homologue proteins. A.
Sequence alignment of VEB-1 with PER-1, Toho-1 and CTX-M-16. The second structure assignment of PER-1
is labeled on the top of the sequences. B. Cartoon representation of the overall structure of VEB-1 is in light
orange color. The serine active-site is colored in red, the SDN motif in green.
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contacts in the geometric chain. Each model of VEB-1 was optimized using the vari-
able target function method (VTFM) with conjugate gradients (CG), followed by fur-
ther refinement using molecular dynamics (MD) with a simulated annealing (SA) method
in Modeller [25]. Energy minimization was performed to minimize stearic collisions and
strains without significantly altering the overall structure. Energy computations and
minimization were carried out using the GROMOS96 force field [26] and implementing
Swiss-PdbViewer. After optimization the 3D model of VEB-1 was verified using the
PROCHECK [27], ERRAT [28] and VERIFY 3D [29] programs available from the Struc-
tural Analysis and Verification Server (SAVES) (http://nihserver.mbi.ucla.edu/SAVES).
PROCHECK was used to assess the stereochemical quality of the protein structure, while
the Verify3D program analyzed the compatibility of an atomic model (3D) with its own
amino acid sequence (1D) to assess the 3D protein structure.
Screening of compounds from the ZINC Database
Ligand-based virtual screening experiments are important during the early stages of drug
discovery, as they can screen compound databases using the active sites of proteins with
known 3D structure. The ZINC Database [30] is free to use and contains commercially
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million compounds in ready-to-dock, 3D formats that can be purchased. During this work
the ZINC Database was screened for structurally similar inhibitors of VEB-1 β-lactamases.
The compounds identified included clavulanic acid, sulbactam, tazobactam, imipenem,
cefoxitin and moxalactam. Furthermore, this study identified 950 compounds that were
structurally similar to available Amber class A β-lactamase inhibitors during screening.
Structure-based virtual screening using molecular docking
Virtual screening uses computational methods to identify molecules that are biologic-
ally active against a specific protein target [31]. Two types of methodologies can be
used during virtual screening: those that search for similarity to validated ligands, and
molecular docking methods that require structural information about the target.
During this study the first method, which is also known as ligand-based virtual screening,
was utilized. Analogs with a minimum of 70% similarity to the known β-lactamase inhibi-
tors (clavulanic acid, sulbactam, tazobactam, imipenem, cefoxitin and moxalactam) were
selected from the ZINC database. To remove structural redundancies from the chemical
library, structurally similar compounds with a Tanimoto coefficient larger than 0.8 were
clustered into a single representative molecule. As a consequence, a docking library
consisting of 950 compounds was obtained and downloaded in mol2 format.
Virtual screening was performed by docking the inhibitors obtained from the ZINC
database to the active site of the VEB-1 protein using AutoDock Vina software
(version 1.0) [32]. This docking allowed a population of possible conformations and
orientations for the ligand at the binding site to be obtained. Using the Autodock Tools
software [33], polar hydrogen atoms were added to VEB-1 protein, and its non-polar
hydrogen atoms were merged. The protein receptor (VEB-1) and inhibitors were
converted from PDB format to PDBQT format. All bonds within ligands were set to allow
rotation. In the configuration file of the Autodock Vina software, a grid box with
dimensions of 20 × 20 × 20 points was used around the active site to cover the entire
enzyme binding site and allow ligands to move freely.
The docking simulation of each compound was conducted using an improved empir-
ical AutoDock scoring function, in which a new solvation model for organic molecules










































where WvdW, Whbond, Welec, Wtor andWsol are the weighting factors of van der Waals,
hydrogen bond, electrostatic interactions, torsional term and desolvation energy of the in-
hibitors, respectively. rij represents the interatomic distance, and Aij, Bij, Cij and Dij are
related to the depths of the potential energy well and the equilibrium separations between
the two atoms. The hydrogen bond term has an additional weighting factor, E(t),
representing the angle-dependent directionality. The cubic equation approach was applied
to obtain the dielectric constant required for computing the interatomic electrostatic
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number of sp3 bonds in the ligand. In the desolvation term, Si and Vi are the solvation par-
ameter and the fragmental volume of atom i, [35] respectively, while Occimax is the max-
imum atomic occupancy. In the calculation of the molecular solvation free energy term in
Eq. (1), the atomic parameters developed by Kang et al. [36] were used, as only carbon
atoms were available. This modification of the solvation free energy term is expected to in-
crease the accuracy of virtual screening, as underestimation of ligand solvation can lead to
overestimation of the binding affinity of a ligand with several polar atoms [37].
The best conformation with the lowest docked energy was chosen from the docking
search. The interactions of complex VEB-1 protein-ligand conformations including
hydrogen bonds and bond lengths were analyzed using Swiss-PdbViewer v4.0 [38],
Pymol software [39], UCSF Chimera [40] and Accelrys DS Visualizer software [41]. The
commercially available software toxtree (developed by Idea consult Ltd., Sofia, Bulgaria)
was used for computer-based estimation of chemical toxicity [42].Results and Discussion
Protein homology modeling and validation
Multiple sequence alignment of VEB-1 with PER-1, CTX-M-16 and Toho-1 β-lactamases
demonstrated that VEB-1 is highly homologous to PER-1 type β-lactamases (38% se-
quence identity) (Figure 1A). The BLASTP homology search using the E. coli VEB-1 β-
lactamase sequence against the PDB database confirmed this result (data not shown). In
addition, sequence alignment indicated that VEB-1 contains a serine-valine-methionine-
lysine tetrad (SXXK) at positions 70–73, including the conserved serine and lysine amino
acid residues that are characteristic of β-lactamases with a serine active site [43]. Several
other structural elements characteristic of class A β-lactamases were identified including a
serine-aspartate-asparagine (SDN) motif at positions 135–137, and lysine-threonine-argin-
ine (KTG) residues at positions 239–242 (Figure 1A.). Accordingly, the crystal structure of
PER-1 β-lactamase from P. aeruginosa (PDB ID: 1E25) was used as the template during
homology modeling.
The modeled enzyme is a monomer, folded into an α/β domain consisting of a seven-
stranded β-sheet and 11 α-helices (Figure 1B.). The residues in the Ser135-Asp136
-Asn137 (SDN) motif are involved in maintaining the structure of the active site cavity,
enzyme stability and stabilization of the enzyme transition state, respectively [44].
Ser135, a conserved amino acid among all class A β-lactamases, is occasionally replaced
by a Gly residue. The multiple roles of this residue include anchoring β-lactams to the
active site, and stabilizing it, through hydrogen bonding with the C-3/C-4 carboxylates
of inhibitors and substrates and facilitating proton transfer to the β-lactam nitrogen
during acylation, leading to opening of the β-lactam ring [45].
The quality of the 3D model was evaluated via the Ramachandran plot using
PROCHECK software (Figure 2). The Ramachandran plot for the predicted model re-
vealed that 88.2% of residues were in the most favorable region, while 10.6% were in
the allowed region, confirming that the predicted model is of good quality. ERRAT is a
so-called “overall quality factor” for non-bonded atomic interactions, with higher scores
indicating higher quality. The generally accepted range is >50 for a high quality model.
For the current 3D model, the overall quality factor predicted by the ERRAT server was
Plot statistics
Residues Percentage
Residues in most favored regions [A, B, L] 88.2%
Residues in additional allowed regions [a, b, l, p] 10.6%
Residues in generously allowed regions [-a, -b, -l, -p] 1.2%
Residues in disallowed regions 0%
Figure 2 Ramachandran plot of VEB-1 β-lactamase model from Escherichia coli obtained by
PROCHECK: 88.2% residues in favorable regions; 10.6% residues in additional allowed regions; 1.2%
residues in generously allowed regions; 0% residues in disallowed regions.
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β-lactamase had an average 3D-1D score > 0.2, thereby verifying the model.Virtual screening result analysis
Following docking simulations, the four most promising inhibitors were selected on the
basis of binding affinity (Figure 4). Among the six categories of Amber class A β-
lactamase inhibitors considered during the analysis, the optimal interactions with the
highest affinity scores were obtained with sulbactam analogs. This finding was contrary to
previous results for SHV-1 Amber class A β-lactamase, and sulbactam is a less potent in-
hibitor than clavulanate [46]. Sulbactam is more potent against class C β-lactamases than
clavulanate, whereas its activity against class D enzymes is less potent than against class A
β-lactamases. Similarly, sulbactam does not inhibit OXA-type enzymes as efficiently as
TEM-1 and other clinically used inhibitors [47].
The best conformation demonstrated that the free energy of binding (ΔGbind, kcal/mol)
for the top four inhibitors was good. The negative and low value of ΔGbind (-6.4) indi-
cated strong bonds between VEB-1 and the ZINC4085364 inhibitor, and demonstrated
that the inhibitor was in its most favorable conformation. Analysis of the docked com-
plexes demonstrated that the inhibitor was located close to the active site (Ser68), at a dis-
tance of 0.6 Å. The complex was stabilized by four hydrogen bonds through residues
Ser68, Lys71, Ser131 and Gln67 (Figure 5B). The residue involved in cavity formation is
presented in Figure 5A. Interaction analysis revealed that the cavity involved in the
Figure 3 Errat plot for the VEB-1 β-lactamase model. Black bars identify the misfolded region located
distantly from the active site, gray bars demonstrate the error region between 95% and 99%, and white
bars indicate the region with a lower error rate for protein folding.
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estimate toxic properties. Finally, four molecules were selected (Table 1).Conclusions
Antibiotic resistance is one of the most serious threats to public health. Development
of resistance is assisted by the existence of plasmids, which can be transmitted easily
between bacteria. The emergent VEB-1 β-lactamase possesses potent hydrolysis activityS.No Ligands (ZINC ID)  Structure of molecule Binding Affinity 
(Kcal/mol) 
1 ZINC4085364 -6.4 
2 ZINC5455944. -5.39 
3 ZINC4501895 -5.18 
4 ZINC5625293 -5.14
Figure 4 Estimated Free Energy of Binding of the top four ligands.
Figure 5 Binding interactions of inhibitors demonstrating maximum binding affinity (ZINC4085364),
and the modeled VEB-1 protein. The left presents the structural electrostatic surface, and the right the
detailed binding interactions. (hydrogen bond interactions are indicated with blue dotted lines).
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ant tool for exploring biologically relevant chemical spaces, and allows studies focused
on small molecule libraries to be performed, using up to millions of compounds. Dur-
ing the present study, structural models of a VEB-1/ZINC4085364 inhibitor complex
were obtained using homology modeling and molecular docking methods. At present,
there are no effective antibiotics against VEB-1-positive pathogens. An appropriate
strategy involves identifying drug candidates from existing antibiotics, such as cephalo-
sporin, on the basis of the 3D model of VEB-1 using structure-based virtual screening.
This strategy was used successfully in the discovery of Merck’s HIV protease inhibitor
[48]. The molecule identified in the current study as a VEB-1 inhibitor could be
exploited for drug design. However, further in vivo experimentation is required for
complete evaluation.Table 1 Physiochemical properties of the most potent ligand (ZINC4085364) obtained
from the docking study
pH range Reference (pH 7)
xlogP −1.64
Apolar desolvation (kcal/mol) −7.31
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